AI Article Synopsis
- CD44 is a variable adhesion molecule, with the isoform CD44v6 linked to metastasis and poor outcomes in colon cancer, but research in breast cancer is inconsistent.
- In a study of 338 patients with primary breast tumors, the expression of CD44v6 was assessed, revealing that 64.8% tested positive.
- Despite this high positivity rate, CD44v6 did not show any prognostic value for disease-free or overall survival in breast cancer patients.
Article Abstract
Background: CD44 is an adhesion molecule and represents a highly variable family of isoforms. The isoform CD44v6 has been associated with metastasis formation and poor prognosis in animal models and human colon cancer. Results of studies in primary breast cancer are relatively small and contradictory.
Patients And Methods: The immunohistochemical expression of CD44v6 was studied in a series of 338 patients with primary breast tumours, uniformly staged and treated in a single center with a long median follow-up of 128 months. The prognostic significance of CD44v6 as well as the correlation with several clinicopathological features were analysed.
Results: Two hundred nineteen of 338 (64.8%) of the breast cancer were CD44v6-positive (> 5% of tumour cells with positive staining). CD44v6 expression had no value for prognosticating disease-free or overall survival at this or any other cut-off point.
Conclusion: CD44v6 expression is not a prognostic factor in primary breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1008220917687 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!